EFEric Frechette

Eric Frechette

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eric Frechette has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Short report: interim safety results for a phase II trial measuring the integration of stereotactic ablative radiotherapy (SABR) plus surgery for early stage non-small cell lung cancer (MISSILE-NSCLC)

    by David A. Palma, Timothy K. Nguyen, Keith Kwan, Stewart Gaede, Mark Landis, Richard Malthaner, Dalilah Fortin, Alexander V. Louie, Eric Frechette, George B. Rodrigues, et al.

    A phase II trial was launched to evaluate if neoadjuvant stereotactic ablative radiotherapy (SABR) before surgery improves oncologic outcomes in patients with stage I non-small cell lung cancer (NSCLC). We report a mandated interim safety analysis for the first 10 patients who completed protocol treatment. Operable patients with biopsy-proven T1-2 N0 NSCLC were eligible. SABR was delivered using a risk-adapted fractionation (54Gy/3 fractions, 55/5 or 60/8). Surgical resection was planned 10 weeks later at a high-volume center (>200 lung cancer resections annually). Patients were imaged with dynamic positron emission tomography-computed tomography scans using 18F-fludeoxyglucose (18F-FDG-PET CT) and dynamic contrast-enhanced CT before SABR and again before surgery. Toxicity was recorded using CTCAE version 4.0. Twelve patients were enrolled between 09/2014 and 09/2015. Two did not undergo surgery, due to patient or surgeon preference; neither patient has developed toxicity or recurrence. For the 10 patients completing both treatments, median age was 70 (range: 54–76), 60% had T1 disease, and 60% had adenocarcinoma. Median FEV1 was 73% predicted (range: 54–87%). Median time to surgery post-SABR was 10.1 weeks (range: 9.3–15.6 weeks). Surgery consisted of lobectomy (n = 8) or wedge resection (n = 2). Median follow-up post-SABR was 6.3 months. After combined treatment, the rate of acute grade 3–4 toxicity was 10%. There was no post-operative mortality at 90 days. The small sample size included herein precludes any definitive conclusions regarding overall toxicity rates until larger datasets are available. However, these data may inform others who are designing or conducting similar trials. NCT02136355 . Registered 8 May 2014.


  • Open Access

    Identifying Primary Spontaneous Pneumothorax from Administrative Databases: A Validation Study

    by Eric Frechette, Keegan Guidolin, Ayman Seyam, Yun-Hee Choi, Sarah Jones, J. Andrew McClure, Jennifer Winick-Ng, Blayne Welk, Richard A. Malthaner

    Introduction. Primary spontaneous pneumothorax (PSP) is a disorder commonly encountered in healthy young individuals. There is no differentiation between PSP and secondary pneumothorax (SP) in the current version of the International Classification of Diseases (ICD-10). This complicates the conduct of epidemiological studies on the subject.Objective. To validate the accuracy of an algorithm that identifies cases of PSP from administrative databases.Methods. The charts of 150 patients who consulted the emergency room (ER) with a recorded main diagnosis of pneumothorax were reviewed to define the type of pneumothorax that occurred. The corresponding hospital administrative data collected during previous hospitalizations and ER visits were processed through the proposed algorithm. The results were compared over two different age groups.Results. There were 144 cases of pneumothorax correctly coded (96%). The results obtained from the PSP algorithm demonstrated a significantly higher sensitivity (97% versus 81%,p=0.038) and positive predictive value (87% versus 46%,p<0.001) in patients under 40 years of age than in older patients.Conclusions. The proposed algorithm is adequate to identify cases of PSP from administrative databases in the age group classically associated with the disease. This makes possible its utilization in large population-based studies.


    • 4 March 2011
      • Vol. 59  (4) , 201-3

    [Video-assisted thoracoscopic lobectomy--the treatment of choice for stage I NSCLC].

    by Ciprian Bolca, Matias Losano Brontos, Massimo Conti, Eric Fréchette

    Video-assisted thoracic surgery (VATS) in the diagnosis and treatment of stage I NSCLC has been used since the early 1990s. This report aims to provide a retrospective analysis of the literature in order to present the advantages of VATS lobectomy compared with open resection. The best available evidence strongly suggests that VATS lobectomy is less morbid than open lobectomy, the postoperative quality of life is superior and long-term oncologic results are equivalent. All these data supports the idea that VATS lobectomy is the treatment of choice for stage I NSCLC.